|
|||||
|
|
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors |
|
| Authors: | Yuan Yuan Deirdre J. Cohen Erica Love Michelle Yaw Benjamin Levinson Steven J. Nicol Howard S. Hochster |
| Affiliation: | (1) Loma Linda University Cancer Center, 11175 Campus Street, Loma Linda, CA 92354, USA;(2) New York University Cancer Institute, 160 E 34th Street, New York, NY 10016, USA;(3) Division of Biostatistics, New York University School of Medicine , 650 First Avenue, New York, NY 10016, USA;(4) Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA;(5) Yale Cancer Center, 333 Cedar Street, Box 208028, New Haven, CT 06520, USA; |
| Abstract: | PurposeTo determine the maximum tolerated dose (MTD) and the recommended phase II dose and to identify the dose-limiting toxicities (DLTs) of gemcitabine, administered by fixed-dose rate (FDR) infusion, combined with the antifolate agent pemetrexed in patients with advanced solid tumors. |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |